NCT01819870 - Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

May 31, 2013

Study Completion Date

August 31, 2013

Conditions

Essential HypertensionChronic Stable AnginaCongestive Heart Failure

Interventions

DRUG

Dilatrend SR capsule 32mg

"* 1 capsule, oral, once daily, 7days~* over the period I\&II(crossover)"

DRUG

Dilatrend IR tablet 25mg

"* 1 tablet, oral, once daily, 7days~* over the period I\&II(crossover)"

Trial Locations (1)

Kyungpook National University Hospital Clinical Trial Center, Daegu